Effects of Butylphthalide combined with Alteplase intravenous thrombolysis in the treatment of patients with acute cerebral infarction
Objective:To observe effects of Butylphthalide combined with Alteplase intravenous thrombolysis in treatment of patients with acute cerebral infarction.Methods:A prospective study was conducted on 120 patients with acute cerebral infarction admitted to the hospital from October 2018 to October 2022.According to the random number table method,they were divided into observation group and control group,60 cases in each group.The control group was treated with intravenous thrombolysis with Alteplase,while the observation group was treated with oral Butylphthalide soft capsules on the basis of that of the control group.The National Institutes of Health stroke scale(NIHSS)score,the serum inflammatory factors[interleukin(IL)-2,IL-6,C-X-C chemokine ligand 12(CXCL12),recombinant human soluble CD40 ligand(sCD40L)]levels,the serum neuron specific enolase(NSE)level,the serum homocysteine(Hcy)level,the mini-mental state examination(MMSE)score,and the incidence of adverse reactions were compared between the two groups.Results:After the treatment,the MMSE scores of the two groups were higher than those before the treatment,and that in the observation group was higher than that in the control group;the NIHSS score and the serum levels of CXCL12,sCD40 L,IL-6,IL-2,NSE and Hcy in the two groups were lower than those before the treatment,and those in the observation group were lower than those in the control group;and the differences were statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Butylphthalide combined with Alteplase intravenous thrombolysis in the patients with acute cerebral infarction can improve the MMSE scores,and reduce the serum NSE,Hcy,inflammatory factor levels and the NIHSS scores.Moreover,it is superior to single Alteplase intravenous thrombolysis treatment.